XTMAB-16

DRUG5 trials

Sponsors

Xentria Inc., Xentria, Inc.

Conditions

Pulmonary SarcoidosisPulmonary sarcoidosis with or without extrapulmonary manifestations

Phase 1

A seamless, phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations

WithdrawnCTIS2022-502877-41-00

Xentria Inc.Pulmonary sarcoidosis with or without extrapulmonary manifestations

Target: 47Updated: 2023-09-04

A seamless, phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations

RecruitingCTIS2022-502877-41-01

Xentria Inc.Pulmonary sarcoidosis with or without extrapulmonary manifestations

Start: 2025-02-10Target: 24Updated: 2025-07-18

Phase 2

An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

Active, not recruitingNCT06169397

Xentria, Inc.Pulmonary Sarcoidosis

Start: 2024-03-01End: 2026-11-01Updated: 2026-08-21

A Long-term Multicenter Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra pulmonary Involvement

Not yet recruitingCTIS2023-507590-18-00

Xentria Inc.Pulmonary sarcoidosis with or without extrapulmonary manifestations

Target: 24Updated: 2025-07-09

An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

Not yet recruitingNCT07680166

Xentria, Inc.Pulmonary Sarcoidosis

Start: 2026-10-30End: 2029-10-31Target: 182Updated: 2026-08-31

Related Papers

XTMAB16 Study: A Phase 2, Randomized, Double-blind Clinical Trial Investigating the Safety and Efficacy of Intravenous XTMAB-16 Versus Placebo in Patients With Pulmonary Sarcoidosis

American Journal of Respiratory and Critical Care Medicine2025-05-011 citations